158 related articles for article (PubMed ID: 16023642)
21. Leishmania donovani: dynamics of L. donovani evasion of innate immune cell attack due to malnutrition in visceral leishmaniasis.
Kumar V; Bimal S; Singh SK; Chaudhary R; Das S; Lal C; Pandey K; Das VR; Das P
Nutrition; 2014 Apr; 30(4):449-58. PubMed ID: 24607302
[TBL] [Abstract][Full Text] [Related]
22. Leishmania donovani: evolution and architecture of the splenic cellular immune response related to control of infection.
Melby PC; Tabares A; Restrepo BI; Cardona AE; McGuff HS; Teale JM
Exp Parasitol; 2001 Sep; 99(1):17-25. PubMed ID: 11708830
[TBL] [Abstract][Full Text] [Related]
23. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
Sharief AH; Gasim Khalil EA; Theander TG; Kharazmi A; Omer SA; Ibrahim ME
Exp Parasitol; 2006 Dec; 114(4):247-52. PubMed ID: 16716301
[TBL] [Abstract][Full Text] [Related]
24. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P
J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477
[TBL] [Abstract][Full Text] [Related]
25. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
Dey R; Majumder N; Bhattacharyya Majumdar S; Bhattacharjee S; Banerjee S; Roy S; Majumdar S
Scand J Immunol; 2007 Dec; 66(6):671-83. PubMed ID: 18021365
[TBL] [Abstract][Full Text] [Related]
26. Problems in the treatment of kala-azar: case report.
Nyakundi PM; Rashid JR; Wasunna KM; Were JB; Muigai R; Kirigi G; Mbugua J
East Afr Med J; 1995 Jun; 72(6):406-8. PubMed ID: 7498017
[TBL] [Abstract][Full Text] [Related]
27. Leishmania donovani infection of human myeloid dendritic cells leads to a Th1 response in CD4+ T cells from healthy donors and patients with kala-azar.
Ghosh M; Mandal L; Maitra S; Rakshit S; Paul K; Bagchi J; Ganguly D; Pal C; Bandyopadhyay S
J Infect Dis; 2006 Aug; 194(3):294-301. PubMed ID: 16826476
[TBL] [Abstract][Full Text] [Related]
28. Ultrastructural study on the antileishmanial effect of 1,2-dimethyl-3-methoxy carbonyl-4-(2-nitro-4,5-dimethoxyphenyl) pyrrole in hamsters.
Bhatnagar S; Maitra SC; Guru PY; Katiyar JC
Indian J Med Res; 1991 May; 93():147-51. PubMed ID: 1657768
[TBL] [Abstract][Full Text] [Related]
29. Role of HLA-DR antigen on T-cell activation in visceral leishmaniasis.
Lal S; Bimal S; Sinha AN; Prasad LS
Indian J Exp Biol; 1991 Dec; 29(12):1101-3. PubMed ID: 1816092
[TBL] [Abstract][Full Text] [Related]
30. Leishmania donovani: influence of anti-leishmanial therapy on expression of lymphocyte function-associated antigen-3 and its relevance to pathogenisis in visceral leishmaniasis.
Shivam P; Jamal F; Kumari S; Bimal S; Narayan S; Das VN; Pandey K; Gupta AK; Singh D; Verma N; Das P; Singh SK
Hum Immunol; 2013 Dec; 74(12):1575-8. PubMed ID: 23974052
[TBL] [Abstract][Full Text] [Related]
31. Differential decline in Leishmania membrane antigen-specific immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-azar patients after chemotherapy.
Anam K; Afrin F; Banerjee D; Pramanik N; Guha SK; Goswami RP; Saha SK; Ali N
Infect Immun; 1999 Dec; 67(12):6663-9. PubMed ID: 10569788
[TBL] [Abstract][Full Text] [Related]
32. Visceral leishmaniasis (kala-azar)--the Bihar (India) perspective.
Sinha PK; Ranjan A; Singh VP; Das VN; Pandey K; Kumar N; Verma N; Lal CS; Sur D; Manna B; Bhattacharya SK
J Infect; 2006 Jul; 53(1):60-4. PubMed ID: 16269185
[TBL] [Abstract][Full Text] [Related]
33. T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani.
Hailu A; van Baarle D; Knol GJ; Berhe N; Miedema F; Kager PA
Clin Immunol; 2005 Nov; 117(2):182-91. PubMed ID: 16125466
[TBL] [Abstract][Full Text] [Related]
34. Antileishmanial drugs cause up-regulation of interferon-gamma receptor 1, not only in the monocytes of visceral leishmaniasis cases but also in cultured THP1 cells.
Dasgupta B; Roychoudhury K; Ganguly S; Kumar Sinha P; Vimal S; Das P; Roy S
Ann Trop Med Parasitol; 2003 Apr; 97(3):245-57. PubMed ID: 12803856
[TBL] [Abstract][Full Text] [Related]
35. Antiparasitic activity of a triphenyl tin complex against Leishmania donovani.
Raychaudhury B; Banerjee S; Gupta S; Singh RV; Datta SC
Acta Trop; 2005 Jul; 95(1):1-8. PubMed ID: 15896700
[TBL] [Abstract][Full Text] [Related]
36. Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis.
Garg R; Gupta SK; Tripathi P; Hajela K; Sundar S; Naik S; Dube A
Vaccine; 2006 Apr; 24(15):2900-9. PubMed ID: 16448729
[TBL] [Abstract][Full Text] [Related]
37. Visceral leishmaniasis: a rare cause of post-transplant fever and pancytopenia.
Rajaram KG; Sud K; Kohli HS; Gupta KL; Sakhuja V
J Assoc Physicians India; 2002 Jul; 50():979-80. PubMed ID: 12126362
[TBL] [Abstract][Full Text] [Related]
38. Leishmania donovanib - knocking the door.
Kamath S; Avi H; Mehta PJ
J Assoc Physicians India; 1995 May; 43(5):315-6. PubMed ID: 9081956
[No Abstract] [Full Text] [Related]
39. Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy.
Carter KC; Hutchison S; Boitelle A; Murray HW; Sundar S; Mullen AB
Parasitology; 2005 Dec; 131(Pt 6):747-57. PubMed ID: 16336728
[TBL] [Abstract][Full Text] [Related]
40. Hypersensitivity reaction over lesions of post-kala-azar dermal leishmaniasis mimicking type 1 reaction in leprosy.
Dhar S; Malakar S
Int J Lepr Other Mycobact Dis; 1999 Mar; 67(1):66-7. PubMed ID: 10407631
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
